

Divergent Innervation of the Olfactory Bulb by Distinct Raphe Nuclei

Raphael Steinfeld,^{1,2} Jan T. Herb,^{1,3,4} Rolf Sprengel,⁵ Andreas T. Schaefer,^{1,3,4,6} and Izumi Fukunaga^{1,4*}

¹Behavioural Neurophysiology, Max Planck Institute for Medical Research, Heidelberg, 69120, Germany

²Champalimaud Centre for Neuroscience, Lisbon, 1400-038, Portugal

³Institute for Anatomy and Cell Biology, University of Heidelberg, Heidelberg, 69120, Germany

⁴Division of Neurophysiology, MRC National Institute for Medical Research, London NW7 1AA, UK

⁵Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Heidelberg, 69120, Germany

⁶Department of Neuroscience, Physiology and Pharmacology, University College London, WC1E 6BT, UK

ABSTRACT

The raphe nuclei provide serotonergic innervation widely in the brain, thought to mediate a variety of neuromodulatory effects. The mammalian olfactory bulb (OB) is a prominent recipient of serotonergic fibers, particularly in the glomerular layer (GL), where they are thought to gate incoming signals from the olfactory nerve. The dorsal raphe nucleus (DRN) and the median raphe nucleus (MRN) are known to densely innervate the OB. The majority of such projections are thought to terminate in the GL, but this has not been explicitly tested. We sought to investigate this using recombinant adeno-associated

viruses (rAAV)-mediated expression of green fluorescent protein (GFP)-synaptophysin targeted specifically to neurons of the DRN or the MRN. With DRN injections, labeled fibers were found mostly in the granule cell layer (GCL), not the GL. Conversely, dense labeling in the GL was observed with MRN injections, suggesting that the source of GL innervation is the MRN, not the DRN, as previously thought. The two raphe nuclei thus give dual innervation within the OB, with distinct innervation patterns. *J. Comp. Neurol.* 523:805–813, 2015.

© 2015 Wiley Periodicals, Inc.

INDEXING TERMS: quantitative image analysis; rAAV; RRIDs: AB_300798; AB_1142794; nlx_153890

Modulation of brain activities, that is, how a given circuit operates in seemingly different modes, has been observed in many brain regions and is likely to be a general property of brain operation across species (Marder, 2012; Bargmann and Marder, 2013; Linster and Fontanini, 2014). Such modulation is thought to involve coordinated changes in a variety of neurons orchestrated by a diffuse network of fibers containing neurotransmitters collectively known as neuromodulators. In contrast to the diffuse and widespread presence of such fibers, neurons containing such neurotransmitters are found in distinct and relatively small nuclei (Dahlstroem and Fuxe, 1964; Nieuwenhuys et al., 1988). The neurotransmitter 5-hydroxytryptamine (5-HT), also known as serotonin, is one of the most studied neuromodulators to date. Collections of serotonergic neurons found in the brain stem known as the raphe nuclei are the brain's major sources of serotonin (Dahlstroem and Fuxe, 1964; Steinbusch, 1981; Jacobs and Azmitia, 1992). What role serotonin plays is an active area of investigation and direct, experimental demonstrations of serotonergic neuromodulation

are beginning to emerge on diverse fronts. To give examples, the activity of dorsal raphe nucleus (DRN) neurons and the corresponding serotonin levels in cortical and subcortical areas are correlated with wakefulness and non-REM sleep characterized by a desynchronized pattern in the EEG (Jacobs and Azmitia, 1992; Thakkar et al., 1998; Portas et al., 2000). Serotonin has also been shown to underlie state transitions from roaming to

Additional Supporting Information may be found in the online version of this article.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Grant sponsor: Max-Planck-Society; Grant number: DFG SPP1392; Grant sponsor: Bauer Stiftung; Grant sponsor: Alexander von Humboldt-foundation and ExcellenzCluster CellNetworks, Germany; Grant sponsor: Medical Research Council, UK; MC_UP_1202/5.

*CORRESPONDENCE TO: Izumi Fukunaga, Division of Neurophysiology, MRC National Institute for Medical Research, London, NW7 1AA, UK. E-mail: ifukuna@nimr.mrc.ac.uk

Received August 1, 2014; Revised November 13, 2014; Accepted November 14, 2014.

DOI 10.1002/cne.23713

Published online January 14, 2015 in Wiley Online Library (wileyonlinelibrary.com)

© 2015 Wiley Periodicals, Inc.

dwelling behaviors in *Caenorhabditis elegans* (Flavell et al., 2014).

The olfactory system, especially the olfactory bulb (OB), is a major recipient of serotonergic innervation (Steinbusch, 1981; McLean and Shipley, 1987; Datiche et al., 1995; Shipley and Ennis, 1996). The OB is also a layered structure, where interneurons present in distinct layers are involved in unique functions, such as signal transformation on different timescales (Fukunaga et al., 2014; Linster and Fontanini, 2014). Dense serotonergic innervation, particularly in the glomerular layer (GL), has been described (McLean and Shipley, 1987). As the first complex processing of olfactory signals occurs in glomeruli, neuromodulation here has a potentially major effect on olfactory functions. For example, activation of 5HT_{2C} receptors in the glomerular layer can excite local interneurons (Hardy et al., 2005; Petzold et al., 2009), in turn inhibiting the olfactory nerve terminals, indicating that serotonergic inputs in the GL can in effect gate incoming olfactory signals (Petzold et al., 2009). In vitro studies also demonstrate that excitatory neurons of the OB, including external tufted and mitral cells, can be activated directly by serotonin (Hardy et al., 2005; Liu et al., 2011; Schmidt and Strowbridge, 2014), outside of the GL (Schmidt and Strowbridge, 2014).

Retrograde tracing studies show that the DRN and the median raphe nucleus (MRN) both provide serotonergic inputs to the OB (McLean and Shipley, 1987). The DRN has also been linked, through direct electrical stimulation, to modulation of glomerular layer physiology (Petzold et al., 2009). The DRN and MRN are, however, known to be distinct, with mostly nonoverlapping projection patterns in other brain regions (Jacobs and Azmitia, 1992). It is therefore a prerequisite to establish their innervation pattern in the OB for studying how neuromodulation is implemented in the OB.

Earlier anatomical studies did not explicitly distinguish the two sources of ascending inputs to the OB. We sought to revisit this question by using recombinant adeno-associated viruses (rAAVs) for anterograde tracing. Specifically, we expressed enhanced green fluorescent protein (EGFP) fused to synaptophysin to augment visualization of presynaptic terminals (Nakata et al., 1998; Li and Murthy, 2001; Oh et al., 2014). We thus aimed to target distinct raphe nuclei with small injections to establish the precise termination patterns of ascending projections in the olfactory bulb, specifically with respect to the distinct layers.

MATERIALS AND METHODS

Animal experiments were performed in compliance with the German animal welfare law. rAAV was pre-

pared as previously described (During et al., 2003). A mixture of rAAVs was used for expression of EGFP-synaptophysin fusion protein under the control of the tTA-dependent promoter (Ptet; Zhu et al., 2007) and codon-improved tTA (itTA) under the synapsin or cytomegalovirus (CMV) promoter (Tang et al., 2009). The EGFP-synaptophysin fusion protein composed of EGFP (Zolotukhin et al., 1996) followed by a flexible linker region (AA positions 240–276) and synaptophysin (*Mus musculus*; GB accession number CAA65084; positions AA277–308), with the start codon Met removed. Note that the expression is not required to be conditional.

Stereotactic injections

Mice (C56Bl/6N between 29 and 31 days of age, 15–16 g body mass) were anesthetized with ketamine/xylazine (100 mg/kg and 20 mg/kg intraperitoneally; Inresa Arzneimittel, Freiburg, Germany) and placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA). Lambda and bregma were leveled using an eLeVeLeR (Sigma Technology Systems, East Petersburg, PA) to 12° with bregma lower and a small craniotomy was made at the following coordinates (relative to the bregma): X = 0 mm; Y = -4.525 mm; Z = -2.230 mm for DRN and X = 0 mm, Y = -4.780 mm; Z = -3.350 mm for MRN; 7.9–18.4 nl of rAAV was dispensed through a capillary glass (tip diameter 19–25 μm) using a Nanoject II (Drummond Scientific, Broomall, PA) at 2.3 nl every 10 seconds.

Histology

Solutions used for histology were in phosphate-buffered saline (PBS) that contained (in mM): NaCl (137), KCl (2.8), KH₂PO₄ (1.5), Na₂HPO₄ (8.1) with pH adjusted to 7.4. All chemicals listed were from Sigma-Aldrich (St. Louis, MO) or Merck (Darmstadt, Germany) unless otherwise stated. Fourteen days after the virus injection, animals were sacrificed and perfused transcardially with 4% formalin (pH = 8.9). The whole brain was dissected out, postfixed overnight in 4% formalin at room temperature, washed in PBS, embedded in gelatin (10%), and further fixed overnight in 4% formalin before sagittal sections 50–75 μm thick were cut using a vibratome (Microm HM 650 V; Sigmam Elektronik, Hűffenhardt, Germany).

Alternate sections were treated for Nissl staining with cresyl violet or immunohistochemistry (chicken anti-GFP and goat anti-serotonin AbCam, Cambridge MA; RRIDs: AB_300798 and AB_1142794, respectively; see Table 1). For immunohistochemistry, the sections were incubated in blocking solution (2% bovine serum albumin [BSA], 2% cold fish gelatin, 1% Triton-X100) for 30 minutes, washed in PBS, and incubated with the primary

TABLE 1.
Primary Antibody Information

Antigen	Immunogen	Manufacturer/Cat. No.	Dilution
Serotonin	Serotonin conjugated to BSA with paraformaldehyde.	AbCam, Cambridge, MA (ab66047) RRID: AB_1142794	1:1,000
GFP	Recombinant full-length protein	AbCam, Cambridge, MA (ab13970) RRID: AB_300798	1:1,000

antibodies (1:1,000, diluted to 0.04% blocking solution) for 24 hours. Subsequently, the sections were washed (3×10 minutes) in PBS, incubated with the secondary antibody solution (diluted to 1:500 in $2 \mu\text{g}/\text{ml}$ DAPI (4',6-diamidino-2-phenylindole), and 0.04% blocking solution for 12 hours. Secondary antibodies used for serotonin and EGFP stainings were antigoat conjugated to Cy3 and antichickon conjugated to Alexa Fluor 488 (both diluted to 1:500; Jackson ImmunoResearch Laboratories, West Grove, PA). The antibody against GFP is used widely and known to stain various reporter lines bearing EGFP transgene but not wildtype animals. Distribution patterns of antiserotonin signals in the brainstem, as well as the OB, closely match the patterns reported earlier (Steinbusch, 1981; Takeuchi et al., 1982; McLean and Shipley, 1987; Zhang et al., 2013).

Image processing

Confocal fluorescence images were obtained with a Leica SP 5 (Leica Microsystems, Mannheim, Germany) with a $\times 63$ glycerol immersion objective (HCX PL APO, NA 1.30, Leica). Laser wavelengths of 405, 458, or 561 nm were used for DAPI, Alexa Fluor 488, or Cy3 signals, respectively, and recorded separately. The pictures were stitched with Leica Confocal Software (v. 2.6.0.7266, Leica Microsystems, Mannheim, Germany). Nissl-stained sections were imaged with a brightfield microscope (Stemi SV11, Zeiss, Oberkochen, Germany). All images were analyzed in Fiji (Schindelin et al., 2012) and MatLab (MathWorks, Natick, MA; RRID: nlx_153890). Fluorescently labeled cells in the DRN and MRN were manually counted (repeated three times to account for

manual error). Identified cells were marked independently in the red and green channels and colocalization was determined by the proximity of the labels, with a cutoff distance of $12 \mu\text{m}$. Detected colocalization was robust to minor changes in the cutoff distance. Subdivisions of the raphe nucleus were manually delineated based on structures visible in the adjacent Nissl-stained sections and 5-HT immunoreactivity in the same section. Definitions of the MRN and the DRN were based on Jacobs and Azmitia (1992), corresponding to B8 and B5 (also known as the nucleus centralis superior) and B7 and B6 (Dahlstroem and Fuxe, 1964), respectively.

Detection of labeled fibers in the OB

For each animal, a coronal section approximately at the middle level of anteroposterior axis of the OB was selected for analysis. The results are qualitatively the same at various anteroposterior levels (data not shown). Confocal fluorescent images taken at high resolution ($\times 63$) were tiled together to reconstruct the entire coronal section. Ten samples ($120 \times 120 \mu\text{m}$ each) were taken from each OB layer, based only on the structures visible in the DAPI channel in order not to be biased by the locations of labeled fibers. Samples covered all mediolateral and dorsoventral positions equally, where approximately one sample was placed randomly within each 36° sector. Different sampling coordinates were used for each animal, as the shape of the OB differed between animals, ensuring that samples placed in distinct OB layers did not sample other layers. Each sample was denoised ("despeckle" function) and the background subtracted ("subtract background" function with radius set to $30 \mu\text{m}$) in Fiji. The mean and standard deviation of pixel values from all samples were calculated for each animal ("global mean and standard deviation" per animal). Fluorescent signal was defined to be pixel values above the global mean + 6 standard deviations. Our overall findings are not sensitive to the exact cutoff values. Signal density was defined as the number of detected pixels normalized by the total number of pixels analyzed, and calibrated by the image resolution (~ 7 pixels/ $1 \mu\text{m}$) to obtain the units reported ($\mu\text{m}^2/100 \mu\text{m}^2$). Colocalization measure of EGFP and serotonin signals was based on a method previously described (van Steensel et al., 1996). Briefly, Pearson's correlation

TABLE 2.
Abbreviations Used in Figures

Abbreviation	Key
OB	Olfactory bulb
GL	Glomerular layer
EPL	External plexiform layer
GCL	Granule cell layer
DRN	Dorsal raphe nucleus
MRN	Median raphe nucleus
mif	Medial longitudinal fascicle
CLI	Caudal linear nucleus of raphe
scp	Superior cerebellar peduncle
DTg	Dorsal tegmentum




Figure 1. OB is densely innervated by serotonergic fibers. **(A)** Left: Illustration of a coronal section of the mouse main olfactory bulb showing the layered structure: GL = glomerular layer, EPL = external plexiform layer and GCL = granule cell layer. Top: Maximum projection showing 5-HT immunofluorescence (red) with respect to the OB layers. DAPI signal appears blue. Areas demarcated by white boxes are magnified below. White arrowheads indicate examples of 5-HT immunofluorescence in the EPL and GCL. **(B)** Summary quantification of serotonin immunofluorescence in the GL, EPL, and GCL ($n = 7$ animals). Scale bars = 20 μm .

coefficients were calculated between red and green pixel intensities over a range of image shift (dx) for each volume. A presence of colocalization results in a distinct peak at $dx = 0$ (van Steensel et al., 1996). This was compared against image sets where one channel was rotated by 90° (control rotated images).

RESULTS

Serotonergic fibers densely innervate the glomerular layer

Neurons in the OB are arranged in distinct layers (Fig. 1A) occupied by distinct interneuron classes (Shepherd, 1974). It is therefore important to resolve the serotonergic innervation pattern with respect to these layers. To this end, we carried out immunohistochemistry using an antibody against 5-HT. Intense labeling was observed in fibers located in the glomerular layer ($0.014 \pm 0.003 \mu\text{m}^2/100 \mu\text{m}^2$, $n = 7$ animals; Fig. 1A,B). In addition, some fibers in the EPL and GCL were labeled, but were sparser ($0.0007 \pm 0.0002 \mu\text{m}^2/100 \mu\text{m}^2$ and $0.0008 \pm 0.0002 \mu\text{m}^2/100 \mu\text{m}^2$ in EPL and GCL, respectively, $P < 0.01$, one-way analysis of variance [ANOVA] across all layers, $n = 7$ animals; Fig. 1A,B). No brightly labeled somata were visible, confirming previous reports that 5-HT is most densely located in the GL but its origin is purely extrinsic (Takeuchi et al., 1982; McLean and Shipley, 1987; Zhang et al., 2013).

DRN projects to the OB but not to the glomerular layer

Previous reports have strongly linked the DRN to serotonergic modulation in the GL (McLean and Shipley, 1987; Petzold et al., 2009). To test whether the seroto-

nergic fibers here originate in the DRN, we made small injections targeted to the DRN using the rAAVs for EGFP-synaptophysin expression (see Materials and Methods). Four out of five animals injected were found to have substantial infection in the dorsal raphe, confirmed by the location of 5-HT immunoreactivity and nearby structures visible in Nissl stains in the adjacent sections in each animal (Fig. 2A). An analysis of the injection site revealed that 303 ± 55 cells expressed EGFP in the planes treated for immunohistochemistry (Fig. 2A,B), where 43 ± 60 cells were additionally immunoreactive for 5-HT, indicating that significant numbers of DRN serotonergic neurons were infected. Importantly, the injections left MRN largely uninfected (11 ± 8 cells infected in MRN; Fig. 2A,B).

Following the DRN injections, numerous brightly labeled fibers were visible in the OB (Fig. 2C). The majority of the labeled fibers were located in the GCL (EGFP signal density in GCL = $0.012 \pm 0.004 \mu\text{m}^2/100 \mu\text{m}^2$; $70 \pm 12\%$ of signal in the OB). EGFP labeling was hardly present in the glomerular or the external plexiform layer ($0.001 \pm 0.001 \mu\text{m}^2/100 \mu\text{m}^2$ and $0.003 \pm 0.001 \mu\text{m}^2/100 \mu\text{m}^2$ in GL and EPL, respectively, $P = 0.04$, one-way ANOVA across layers; Fig. 2D), even though immunostaining confirmed the ample presence of 5-HT-containing fibers in the GL for each animal.

MRN is the source of serotonergic fibers in the GL

The above results suggest that the DRN does not project to the GL, raising the question as to the source of the serotonergic innervation in the glomerular layer. The MRN is a potential source, as this nucleus also contains




Figure 2. DRN projects preferentially to the GCL, not the GL. **(A)** Experimental configuration (top left): rAAV was injected into the DRN for expression of EGFP-synaptophysin for anterograde tracing. Bottom: Example of injection site (sagittal view); anatomical details visible in a Nissl-stained, adjacent section (left) were used to demarcate relevant structures in the fluorescent image (middle; maximum projection, green and red signals indicate EGFP and 5-HT immunofluorescence, respectively). Region demarcated in the white box is shown on the right. Dorsal raphe nucleus (DRN), mlf (medial longitudinal fascicle), CLI (caudal linear nucleus of raphe), superior cerebellar peduncle (scp), median raphe nucleus (MRN) and dorsal tegmentum (DTg). Magenta-green copies of the fluorescent images are available in Supplementary Fig. 1. **(B)** Summary quantification; numbers of infected cells counted in DRN or MRN. $n = 4$ animals. **(C)** Location of EGFP-labeled fibers within the OB following DRN injections. Left: Schematic showing the approximate location where the OB images below were taken. Top: Overview image showing the OB layers seen with DAPI (blue) overlaid with immunofluorescence for 5-HT (red) and EGFP (green; maximum projection depicted). Squares indicate the areas magnified below. Bottom: Example high-magnification image from the GL (left) shows dense 5-HT signal (red) but no EGFP signal while the example from GCL (right) shows dense EGFP labeling. Three color channels as above. See magenta-green copy in Supplementary Fig. 2. **(D)** Summary quantification showing EGFP signal densities in GL, EPL, and GCL for DRN injections. $*P = 0.043$, n.s. = not significant; $P = 0.095$ and 0.89 for EPL vs. GCL and GL vs. EPL, respectively; Tukey HSD post-hoc tests. Scale bars = 0.5 mm in A; $20 \mu\text{m}$ in C.

serotonergic neurons (Steinbusch, 1981; McLean and Shipley, 1987; Jacobs and Azmitia, 1992) and is reported to project to the OB (McLean and Shipley, 1987). In order to test this, we made small injections of rAAV-EGFP-synaptophysin viruses targeted to the MRN. Three out of six animals were confirmed to have sufficient

numbers of MRN neurons infected (127 ± 26 infected neurons, Fig. 3A; $20 \pm 6\%$ immunoreactive for 5-HT). Some DRN neurons located immediately above the MRN were also infected (57 ± 39 cells, Fig. 3A).

Abundant labeling in the OB was observed following MRN injections. In particular, in stark contrast to the

pattern observed with the DRN injections, the majority of the labeling was now in the GL ($0.013 \pm 0.004 \mu\text{m}^2/100 \mu\text{m}^2$, $73.4 \pm 12.4\%$ of all label; Fig. 3B,C), and colocalized with 5-HT (peak correlation coefficient at 0.02 ± 0.40 pixel shift; $P < 0.01$ paired *t*-test for significant difference from the rotated image sets, $n = 3$; Fig. 3C-E). Furthermore, combining data from the two injection protocols revealed that the relative amount of labeled fibers in the GCL and GL corresponds tightly to the ratio of infected neurons in the DRN and MRN neurons ($r = 0.84$, $P = 0.017$, $n = 7$ animals; Fig. 3F), indicating that the termination pattern of afferents from the raphe is nucleus-specific, and only the MRN projects to the GL (Fig. 3G).

DISCUSSION

Our localized injections in the two distinct raphe nuclei suggest that the DRN and the MRN have markedly different innervation patterns in the OB: the former projects mainly to the GCL, whereas the latter to the GL. Innervation in the EPL were relatively low in both DRN- and MRN-injected animals.

The lack of labeled fibers in the GL following DRN injections is particularly notable given the previous studies that linked the DRN directly to the serotonergic innervation and neuromodulation in the GL (McLean and Shipley, 1987; Petzold et al., 2009). One obvious consideration is whether the relevant neurons within the DRN have been targeted with our DRN injections. According to a previous retrograde tracing study, all four subdivisions of the DRN innervate the OB (McLean and Shipley, 1987). Our injections covered various rostrocaudal extents, none of which resulted in appreciable labeling of fibers in the GL. The rich labeling in the GCL instead indicates that we targeted the portions of the DRN that project to the OB. It is unlikely that this labeling in the GCL came from unintended infection of other nuclei, such as the locus coeruleus, known to project to the GCL (McLean et al., 1989; Shipley and Ennis, 1996; Linster and Fontanini, 2014), as such nuclei are too far with our small injections to reach. The lack of attention so far given to the GCL innervation is likely due to the sparser serotonin labeling there, observed with antibodies against 5-HT or SERT alike (Takeuchi et al., 1982; McLean and Shipley, 1987; Zhang et al., 2013), in addition to not fully resolving different OB layers or distinct raphe divisions with previous wheatgerm agglutinin injections (McLean and Shipley, 1987). Similarly, it is possible that neuromodulatory effects in the GL that were previously observed through electrical stimulation of the DRN (Petzold et al., 2009) could be attributed to unintended

recruitment of the MRN neurons, as they are located in close proximity to the DRN.

EGFP signals following the MRN injections clearly colocalized with serotonin at least partially in the GL (Fig. 3C-E), making it likely that the MRN is the source of serotonergic innervation here. The partial nature of colocalization observed may in part reflect the possible labeling of passing fibers with this method (see (Oh et al., 2014), as no additional methods, such as staining with FM dyes (Li and Murthy, 2001), were used to distinguish release sites. Collaterals from GL-targeting fibers (Suzuki et al., 2014) may partly explain some signals detected in the GCL following MRN injections, in addition to some contribution from DRN neurons that were also infected at the MRN coordinates. In turn, the dense EGFP labeling in the GCL following the DRN injections seems to outnumber the serotonergic labeling. In addition, no appreciable level of colocalization was detected, bringing into question whether the innervation in the GCL is serotonergic. McLean and Shipley (1987) reported that most anterogradely labeled DRN neurons were serotonergic; therefore, it is possible that the sparse 5-HT labeling here may relate instead to difficulty in detecting labeled fibers, particularly because fibers here are known to be thinner (McLean and Shipley, 1987). GCs themselves seem to express 5HT_{1A} receptors (Pompeiano et al., 1992), but so far in vitro experiments demonstrate a lack of direct GC activation by serotonin (Schmidt and Strowbridge, 2014). However, their postsynaptic partners need not be located in the immediate vicinity of release sites, as serotonin could propagate by volume transmission (Bunin and Wightman, 1999). Another possibility is that the DRN uses other neurotransmitters to innervate the GCL. Indeed, the DRN contains neurons that contain neurotransmitters other than serotonin (Jacobs and Azmitia, 1992), including GABA, dopamine, substance-P, and cholecystokinin (Van Der Kooy et al., 1981; Fu et al., 2010) or glutamate colocalizing in serotonergic neurons (Fu et al., 2010), although some may only project locally (Van Der Kooy et al., 1981). Despite the ambiguity in the transmitter used, what is clear from our study is that the DRN is not the source of serotonergic innervation in the glomerular layer, as commonly assumed.

The nucleus-specific innervation pattern we observe here is reminiscent of largely nonoverlapping projection patterns from the raphe to other brain areas (Steinbusch, 1981; Jacobs and Azmitia, 1992). In addition, the GL and the GCL likely implement distinct functions within the OB, for example gating incoming signals in the GL (Petzold et al., 2009), or transforming signals on different timescales (Fukunaga et al., 2012, 2014; Linster and Fontanini, 2014). Whether the distinct




Figure 3. MRN is the likely source of serotonergic innervation in the GL. **(A)** Experimental configuration (top left): rAAV injections were targeted to the MRN. Example Nissl (bottom left) and fluorescent (middle) images from adjacent sections (maximum projection; red and green signals = 5-HT and EGFP immunofluorescence, respectively) showing infections successfully targeted to the MRN. Region demarcated by the white box is shown magnified (right). Magenta-green copy in Supplementary Fig. 3. **(B)** Summary quantification of EGFP signals in GL, EPL, and GCL following MRN injections ($n = 3$ animals). **(C)** Example from the glomerular layer of the OB; numerous EGFP-labeled fibers (green; maximum projection) in glomeruli are present. DAPI and 5-HT signals appear blue and red, respectively. **(D)** Magnified images from area demarcated on the left image. Some of the EGFP signals (left bottom, green) and 5-HT signals (left top, red) overlap in the merged image (right). Magenta-green copy in Supplementary Fig. 4. **(E)** Quantification of colocalization; Pearson's correlation coefficient for EGFP vs. serotonin signals plotted against image displacement in the x direction (dx). Control corresponds to image sets with one channel rotated by 90° . Mean \pm SEM shown. Displacement in y direction gives equivalent result to dx, and thus not shown. **(F)** Summary plot for DRN and MRN injections; relative abundance of EGFP signals in the GL vs. GCL correlates strongly with relative infection levels in MRN vs. DRN, respectively. Color indicates relative abundance of GFP signals in distinct layers where $[R \ G \ B] = [\log(\text{GFP}_{\text{GL}}/\text{GFP}_{\text{GCL}}) \ 0.8 \cdot (1 - \log(\text{GFP}_{\text{GL}}/\text{GFP}_{\text{GCL}})) \ (1 - \log(\text{GFP}_{\text{GL}}/\text{GFP}_{\text{GCL}}))]$. **(G)** Schematic of the findings; DRN preferentially targets the GCL and EPL, while MRN projects to the GL. Scale bars = 0.5 mm in A; 50 μm in C.

projection patterns by the raphe translate to modulation of specific combination of areas or circuits within a region, and as a result distinct sets of functions, remains to be investigated. Our results indicate that at least in the OB, addressing layer selective neuromodulation may be possible by selective manipulation of distinct raphe nuclei.

ACKNOWLEDGMENTS

We thank Marlies Kaiser and Ellen Stier for technical assistance, Mazahir Hasan, Melanie Bausen, and Verena Bosch for help with the viral constructs, Charly Rousseau for assistance with image processing, Christopher Yeo for helpful discussions, and Ede Rancz for comments on the article. This work was supported generously by the MPG, the DFG-SPP1392, the BMBF (US-German collaboration computational neuroscience), AvH, MRC (MC_UP_1202/5), the ExcellenzCluster CellNetworks, and the Gottschalk foundation.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

IF and ATS conceived the project. RSt carried out the experiments. JTH and RSp designed and contributed viruses. IF and RSt analyzed the data and wrote the article with contributions from all authors.

LITERATURE CITED

- Bargmann CI, Marder E. 2013. From the connectome to brain function. *Nat Methods* 10:483–490.
- Bunin MA, Wightman RM. 1999. Paracrine neurotransmission in the CNS: involvement of 5-HT. *Trends Neurosci* 22:377–382.
- Dahlstroem A, Fuxe K. 1964. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. *Acta Physiol Scand Suppl* 232:231–255.
- Datiche F, Luppi P-H, Cattarelli M. 1995. Serotonergic and non-serotonergic projections from the raphe nuclei to the piriform cortex in the rat: a cholera toxin B subunit (CTb) and 5-HT immunohistochemical study. *Brain Res* 671:27–37.
- During M, Young D, Baer K, Lawlor P, Klugmann M. 2003. Development and optimization of adeno-associated virus vector transfer into the central nervous system. In: Machida C, editor. *Viral vectors for gene therapy*. New York: Humana Press. p 221–236.
- Flavell SW, Pokala N, Macosko EZ, Albrecht DR, Larsch J, Bargmann CI. 2014. Serotonin and the neuropeptide PDF initiate and extend opposing behavioral states in *C. elegans*. *Cell* 154:1023–1035.
- Fu W, Le Maître E, Fabre V, Bernard J-F, David Xu Z-Q, Hökfelt T. 2010. Chemical neuroanatomy of the dorsal raphe nucleus and adjacent structures of the mouse brain. *J Comp Neurol* 518:3464–3494.
- Fukunaga I, Berning M, Kollo M, Schmaltz A, Schaefer AT. 2012. Two distinct channels of olfactory bulb output. *Neuron* 75:320–329.
- Fukunaga I, Herb JT, Kollo M, Boyden ES, Schaefer AT. 2014. Independent control of gamma and theta activity by distinct interneuron networks in the olfactory bulb. *Nat Neurosci* 17:1208–1216.
- Hardy A, Palouzier-Paulignan B, Duchamp A, Royet JP, Duchamp-Viret P. 2005. 5-Hydroxytryptamine action in the rat olfactory bulb: in vitro electrophysiological patch-clamp recordings of juxtglomerular and mitral cells. *Neuroscience* 131:717–731.
- Jacobs BL, Azmitia EC. 1992. Structure and function of the brain serotonin system. *Physiol Rev* 72:165–229.
- Li Z, Murthy VN. 2001. Visualizing postendocytic traffic of synaptic vesicles at hippocampal synapses. *Neuron* 31:593–605.
- Linster C, Fontanini A. 2014. Functional neuromodulation of chemosensation in vertebrates. *Curr Opin Neurobiol* 29:82–87.
- Liu S, Aungst JL, Puche AC, Shipley MT. 2011. Serotonin modulates the population activity profile of olfactory bulb external tufted cells. *J Neurophysiol* 107:473–483.
- Marder E. 2012. Neuromodulation of neuronal circuits: back to the future. *Neuron* 76:1–11.
- McLean JH, Shipley MT. 1987. Serotonergic afferents to the rat olfactory bulb: I. Origins and laminar specificity of serotonergic inputs in the adult rat. *J Neurosci* 7:3016–3028.
- McLean JH, Shipley MT, Nickell WT, Aston-Jones G, Reyher CKH. 1989. Chemoanatomical organization of the noradrenergic input from locus coeruleus to the olfactory bulb of the adult rat. *J Comp Neurol* 285:339–349.
- Nakata T, Terada S, Hirokawa N. 1998. Visualization of the dynamics of synaptic vesicle and plasma membrane proteins in living axons. *J Cell Biol* 140:659–674.
- Nieuwenhuys R, Voogd J, Huijzen C. 1988. Functional systems. In: *The human central nervous system*. Berlin, Heidelberg: Springer. p 143–375.
- Oh SW, Harris JA, Ng L, Winslow B, Cain N, Mihalas S, et al. 2014. A mesoscale connectome of the mouse brain. *Nature* 508:207–214.
- Petzold GC, Hagiwara A, Murthy VN. 2009. Serotonergic modulation of odor input to the mammalian olfactory bulb. *Nat Neurosci* 12:784–791.
- Pompeiano M, Palacios JM, Mengod G. 1992. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. *J Neurosci* 12:440–453.
- Portas CM, Bjorvatn Br, Ursin R. 2000. Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. *Prog Neurobiol* 60:13–35.
- Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682.
- Schmidt LJ, Strowbridge BW. 2014. Modulation of olfactory bulb network activity by serotonin: synchronous inhibition of mitral cells mediated by spatially localized GABAergic microcircuits. *Learn Mem* 21:406–416.
- Shepherd GM. 1974. *The synaptic organization of the brain*. New York: Oxford University Press.
- Shipley MT, Ennis M. 1996. Functional organization of olfactory system. *J Neurobiol* 30:123–176.
- Steinbusch HWM. 1981. Distribution of serotonin-immunoreactivity in the central nervous system of the rat: cell bodies and terminals. *Neuroscience* 6:557–618.

- Suzuki Y, Kiyokage E, Sohn J, Hioki H, Toida K. 2014. Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb. *J Comp Neurol* [Epub ahead of print].
- Takeuchi Y, Kimura H, Sano Y. 1982. Immunohistochemical demonstration of serotonin nerve fibers in the olfactory bulb of the rat, cat and monkey. *Histochemistry* 75:461-471.
- Tang W, Ehrlich I, Wolff SBE, Michalski A-M, Woelfl S, Hasan MT, Luthi A, Sprengel R. 2009. Faithful expression of multiple proteins via 2a-peptide self-processing: a versatile and reliable method for manipulating brain circuits. *J Neurosci* 29:8621-8629.
- Thakkar MM, Strecker RE, McCarley RW. 1998. Behavioral state control through differential serotonergic inhibition in the mesopontine cholinergic nuclei: a simultaneous unit recording and microdialysis study. *J Neurosci* 18:5490-5497.
- Van Der Kooy D, Hunt SP, Steinbusch HWM, Verhofstad AAJ. 1981. Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections. *Neurosci Lett* 26:25-30.
- van Steensel B, van Binnendijk EP, Hornsby CD, van der Voort HT, Krozowski ZS, de Kloet ER, van Driel R. 1996. Partial colocalization of glucocorticoid and mineralocorticoid receptors in discrete compartments in nuclei of rat hippocampus neurons. *J Cell Sci* 109:787-792.
- Zhang J, Dennis KA, Darling RD, Alzghoul L, Paul IA, Simpson KL, Lin RCS. 2013. Neonatal citalopram exposure decreases serotonergic fiber density in the olfactory bulb of male but not female adult rats. *Front Cell Neurosci* 7.
- Zhu P, Aller MI, Baron U, Cambridge S, Bausen M, Herb J, Sawinski Jr, Cetin A, Osten P, Nelson ML, Kügler S, Seeburg PH, Sprengel R, Hasan MT. 2007. Silencing and un-silencing of tetracycline-controlled genes in neurons. *PLoS One* 2:e533.
- Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. 1996. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. *J Virol* 70:4646-4654.